Hydroxychloroquine clinical trial for new coronary pneumonia approved in the US by the US-FDA
According to a recent report from the US Newsweek website,
Novartis Pharmaceuticals, headquartered in Switzerland, said it has reached an
agreement with the US Food and Drug Administration to launch a new anti-malarial
drug hydroxychloroquine treatment in the United States Clinical trials of
hospitalized patients with pneumonia. The entire trial involved 400 patients to
assess the effectiveness of the drug.
According to the US Centers for Disease Control and Prevention,
there are currently no effective therapies and vaccines that can cure new
coronary pneumonia.
In recent weeks, a number of clinical tests have been
conducted around the world to determine whether hydroxychloroquine can relieve
some symptoms of new coronary pneumonia, but the results obtained are very
different.
US President Donald Trump previously said in a White House
briefing and Twitter that the drug has potential therapeutic effects, and that
the United States has stored 29 million hydroxychloroquine, but this has not
been confirmed.
Drugs used in Coronavirus trial
Novartis said that clinical trials will be carried out in
"a dozen places" in the United States, and volunteer recruitment will
begin in the next few weeks. The drugs used in the trials will be provided by
the company's generic and biosimilars departments.
It is reported that in this trial, patients will be randomly
divided into three groups: the first group taking hydroxychloroquine; the
second group taking hydroxychloroquine combined with azithromycin (an antibiotic).
Is hydroxychloroquine beneficial to COVID-19 patients?
The third group taking placebo drugs. John Chua, Chief Medical Officer of
Novartis, said:
"It is very important to answer the scientific question of
whether hydroxychloroquine is beneficial to patients with new coronary
pneumonia. We hope this randomized, placebo-controlled study can solve this
problem."
Novartis plans co-sponsor clinical trials
It is reported that in addition to hydroxychloroquine,
Novartis also plans to sponsor or co-sponsor clinical trials to study the
efficacy of kinase inhibitors lucotinib and canastuzumab in the treatment of
inpatients with new coronary pneumonia.
Author's Bio
![]() |
Dr. Shawna Reason |
Education: MBBS, MD
Occupation: Medical Doctor / Virologist
Specialization: Medical Science, Micro Biology / Virology, Natural Treatment
Experience: 15 Years as a Medical Practitioner
About Me | Linkedin | Quora Profile | Medium Profile | Twitter
Comments
Post a Comment